Faron Pharmaceuticals Oy (LON:FARN) (First North:FARON) said the US Patent and Trademark Office has granted a new patent protecting the composition of matter of its novel precision...
Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) said research has been published supporting the immunotherapeutic blockade of Clever-1 to activate anti-tumour immune...
Faron Pharmaceuticals Oy (LON:FARN) shares moved higher on early deals on the back of promising data from a clinical study of its Bexmarilimab cancer treatment. The company...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Sell | Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.011 | 2.99 | 2.99 | +0.025 | +0.83% | 5.12M | London | |||
| 275.50 | 276.90 | 265.20 | +8.80 | +3.30% | 1.27M | London | |||
| 7.07 | 7.49 | 7.49 | -0.17 | -2.40% | 2.00M | London | |||
| 1,453.60 | 1,486.20 | 1,422.40 | +19.40 | +1.35% | 3.63M | London | |||
| 356.00 | 361.75 | 354.35 | -3.20 | -0.89% | 10.02M | London | |||
| 1,720.50 | 1,738.50 | 1,713.00 | -19.50 | -1.12% | 68.71K | London | |||
| 257.00 | 268.50 | 256.00 | -7.00 | -2.65% | 264.37K | London | |||
| 112.24 | 112.98 | 112.08 | -0.32 | -0.28% | 9.93M | London | |||
| 272.92 | 274.80 | 272.55 | -1.00 | -0.36% | 4.38M | London | |||
| 312.40 | 319.20 | 311.80 | -6.60 | -2.07% | 389.61K | London | |||
| 185.10 | 186.55 | 184.20 | -0.80 | -0.43% | 790.85K | London | |||
| 322.02 | 324.00 | 319.50 | +0.02 | 0.00% | 500.73K | London | |||
| 17.00 | 17.00 | 17.00 | +1.05 | +6.69% | 2.14M | London | |||
| 140.80 | 144.30 | 140.30 | -2.55 | -1.78% | 6.76M | London | |||
| 556.40 | 561.20 | 551.00 | -6.40 | -1.14% | 2.79M | London |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, cardiovascular surgery, CAR-T induced CRS, acute kidney injury, and IRI in solid organ transplantation; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.